What Happened?

Shares of genomics company Illumina (NASDAQ: ILMN) fell 3.2% in the afternoon session after reports emerged of increased competition from a Chinese rival and news of a significant legal settlement. 

The negative sentiment was fueled by a report stating that Chinese biotech firm MGI's DNA sequencers are gaining market share, posing a direct challenge to Illumina's core business. Compounding the pressure, the stock was also impacted by a recent settlement with the Department of Justice (DOJ) to resolve a whistleblower lawsuit. This resolution involves a significant financial payout by the company, raising investor concerns about the financial and reputational implications of the legal challenges, overshadowing any recent positive financial results.

The shares closed the day at $95.12, down 4.3% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Illumina? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Illumina’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 2 days ago when the stock dropped 3.3% as markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. Stocks rose in the morning session after an unexpected drop in the Producer Price Index (PPI) for August signaled easing inflation and raised expectations for a potential Federal Reserve interest rate cut. The U.S. Bureau of Labor Statistics reported that the PPI, which measures wholesale prices, edged down 0.1% the previous month, contrary to analyst expectations for a 0.3% rise. This data gives the Federal Reserve more flexibility to consider lowering interest rates to stimulate the economy.

Illumina is down 27.4% since the beginning of the year, and at $95.12 per share, it is trading 38.7% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of Illumina’s shares 5 years ago would now be looking at an investment worth $268.97.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.